ADPT 241220 12.50C (ADPT241220C12500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Dec 13 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

This_Guy

Dec 8 17:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

This_Guy

Dec 8 17:27

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Positive
Phase 3 trial data shows clonoSEQ can help avoid unnecessary transplantation procedures in MCL patients
FELIX study demonstrated 84% treatment response rate with MRD <10⁻⁶
Evidence supports clonoSEQ's effectiveness in early detection of disease progression
Data validates test'...

Jaguar8

Dec 8 16:19

NEWS SATURDAY 12/7

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Adaptive Biotechnologies (ADPT) presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® test in measuring residual disease (MRD) for blood cancer treatment. Key findings from multiple studies demonstrate that achieving MRD lev...

Jaguar8

Aug 29 07:03

NEWS

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...

TechWhiz

Jun 28 18:55

Good volume move up. Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
Should see higher prices from here.